Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts

Open access
Raiola, Anna Maria, Dominietto, Alida, di Grazia, Carmen, Lamparelli, Teresa, Gualandi, Francesca, Ibatici, Adalberto, Bregante, Stefania, Van Lint, Maria Teresa, Varaldo, Riccardo, Ghiso, Anna, Gobbi, Marco, Carella, Angelo Michele, Signori, Alessio, Galaverna, Federica, Bacigalupo, Andrea·2014·Biology of Blood and Marrow Transplantation

Abstract

We studied 459 consecutive patients with hematologic malignancies, median age 44 years (range, 15 to 71 years), who underwent transplantation with grafts from identical sibling donors (SIB; n = 176), matched unrelated donors (MUD; n = 43), mismatched unrelated donors (mmUD; n = 43), unrelated cord blood (UCB; n = 105) or HLA-haploidentical family donors (HAPLO; n = 92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P = .08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P < .001), and there was a trend toward less moderate-severe chronic GVHD in the HAPLO and UCB groups (P = .053). The proportion of patients off cyclosporine at 1 year ranged from 55% for the SIB group to 81% for the HAPLO group (P < .001). Transplantation-related mortality at 2 years was lower in the HAPLO and SIB groups (18% to 24%) compared with the MUD, mmUD, and UCB groups (33% to 35%; P = .10). Relapse rate was comparable in the 5 groups (P = .80). The 4-year actuarial survival was 45% in the SIB group, 43% in the MUD group, 40% in the mmUD group, 34% in the UCB group, and 52% in the HAPLO group (P = .10). In multivariate analysis, advanced disease was a negative predictor of survival (hazard ratio [HR], 2.4; P < .0001), together with a diagnosis of acute leukemia (HR, 1.8; P = .0001); HAPLO grafts were comparable to SIB (P = .80), whereas UCB had inferior survival (P = .03). In conclusion, unmanipulated haploidentical family donor transplants are an additional option for patients lacking a matched sibling donor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2014.05.029

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 283

Metadata

Authors
Raiola, A. M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., Bregante, S., Van Lint, M. T., Varaldo, R., Ghiso, A., Gobbi, M., Carella, A. M., Signori, A., Galaverna, F., & Bacigalupo, A.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2014-10
Volume
20
Issue
10
Pages
1573-1579
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2010732369
Cited by
283
References
16
FWCI
22.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts. https://app.cochat.ai/papers/10.1016/j.bbmt.2014.05.029
The paper
Raiola, A. M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., Bregante, S., Van Lint, M. T., Varaldo, R., Ghiso, A., Gobbi, M., Carella, A. M., Signori, A., Galaverna, F., & Bacigalupo, A. (2014). Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2014.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.